Cartesian Therapeutics, Inc. (RNAC) · Nov 5, 2026 · Earnings
Beat — EPS $(0.38) vs roughly $(1.01) consensus
Cartesian’s third-quarter earnings beat consensus, helped by liability revaluations, while its AURORA timeline and 2028 cash runway remain intact.
Cartesian is a late-stage autoimmune biotech building toward a potential Descartes-08 launch in myasthenia gravis, with Phase 3 AURORA data expected in the first quarter of 2027 and a planned BLA submission in mid-2027. That broader setup was already established before this quarter; the filing mainly confirms execution and funding rather than changing the development story.
The reported EPS beat is real but not an operating breakthrough. Cartesian posted a $0.38 quarterly loss per share versus a published consensus around $1.01–$1.02, but the gap was driven largely by non-operating gains from changes in the contingent value rights and derivative liabilities, not by revenue or lower core spending. The company still had no revenue in the quarter, while research and development and general and administrative expenses both increased as it funded AURORA and expanded launch-readiness infrastructure.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Revenue (Income Statement) | $0 | $0.45M | $0.16M |
| R&D expense (Income Statement) | $15.6M | $13.8M | |
| G&A expense (Income Statement) | $9.4M | $7.7M | |
| Net loss (Income Statement) | $11.5M | $35.9M | |
| Basic EPS (Income Statement) | $(0.38) | $(1.38) | $(1.01)–$(1.02) |
| Cash, equivalents and restricted cash (Financial Highlights) | $124.7M | ||
| Long-term debt (Balance Sheet) | $50.2M | — |
The clinical timetable is intact, not accelerated. AURORA remains headed toward a first-quarter 2027 readout, while TRITON and HELIOS data remain expected in the first half of 2027. The filing gives no new efficacy result from those programs; the September retreatment data had already been disclosed, so this quarter adds confirmation rather than a fresh clinical proof point.
Funding remains adequate for the next major milestones, but the balance sheet is more leveraged. Cartesian says its $124.7 million of cash, equivalents and restricted cash should support planned operations, including completion of AURORA, into 2028. That runway was already communicated after the K2 HealthVentures financing; the new quarter shows $50.2 million of debt on the balance sheet and continued ATM issuance, so the runway comes with financing obligations rather than being purely cash-funded.
The business is spending ahead of a possible launch without yet producing commercial revenue. R&D rose 13% year over year and G&A rose 22%, reflecting heavier AURORA costs and larger medical-affairs and commercial teams. That is consistent with the company’s stated launch preparation, but it also means the key value-creating event remains the upcoming clinical readout rather than this quarter’s financial performance.
Bottom line: The quarter beats the narrow EPS benchmark, but mainly because of accounting gains rather than better underlying operations. Cartesian remains funded and on schedule for its 2027 clinical catalysts, so this is a modest reinforcement of the existing story—not a rewrite of it.
AURORA Phase 3 data, expected in 1Q27
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!